Risk of leukemia after platinum-based chemotherapy for ovarian cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  New England Journal of Medicine

• Publication date

  1999-02-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM199902043400504PMID 9929525
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical methods in cancer research

  2001cited by this paper
• Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.

  1999cited by this paper
• Cancer statistics, 1998

  1998cited by this paper
• Oral platinum analogue JM216, a radiosensitizer in oxic murine cells.

  1997cited by this paper
• Risk of second malignant neoplasms among long-term survivors of testicular cancer.

  1997cited by this paper
• Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.

  1997cited by this paper
• Second malignant neoplasms among long-term survivors of ovarian cancer.

  1996cited by this paper
• New therapy for ovarian cancer.

  1996cited by this paper
• Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.

  1996cited by this paper
• NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.

  1995cited by this paper
• High-dose intravenous melphalan: a review.

  1995cited by this paper
• Risk of leukemia following treatment for non-Hodgkin's lymphoma.

  1994cited by this paper
• Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

  1993cited by this paper
• 5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study.

  1993cited by this paper
• Advanced epithelial ovarian cancer: 1993 consensus statements.

  1993cited by this paper
• Advanced epithelial ovarian cancer: 1998 consensus statements.

  1993cited by this paper
• Risk of leukemia after chemotherapy and radiation treatment for breast cancer.

  1992cited by this paper
• Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.

  1992cited by this paper
• Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.

  1992cited by this paper
• Is cisplatin a human carcinogen?

  1992cited by this paper
• Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors.

  1990cited by this paper
• Second cancer following chemotherapy and radiotherapy. An epidemiological perspective.

  1990cited by this paper
• Leukemia following Hodgkin's disease.

  1990cited by this paper
• Leukemia following chemotherapy for ovarian cancer

  1990cited by this paper
• Leukemia following chemotherapy for ovarian cancer

  1990cited by this paper
• Tissue doses from radiotherapy of cancer of the uterine cervix.

  1989cited by this paper
• Melphalan may be a more potent leukemogen than cyclophosphamide.

  1986cited by this paper
• High dose cisplatin and high dose carboplatin in refractory ovarian cancer.

  1985cited by this paper
• Statistical methods in cancer research. Vol. 1. The analysis of case-control studies.

  1981cited by this paper
• A computer program for the analysis of matched case-control studies.

  1981cited by this paper
• Cancer Incidence in Five Continents

  1970cited by this paper

• Pharmaceutical pollutants in wastewater treatment plants: A global review of occurrence, treatment efficiency, and implications for receiving water bodies

  2026cites this paper
• Harnessing p53 for targeted cancer therapy: new advances and future directions

  2025cites this paper
• Pt-seq unveils the genomic binding pattern of platinum-based drugs

  2025cites this paper
• Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.

  2025cites this paper
• Cisplatin-induced therapy-related myelodysplastic syndrome during avelumab maintenance therapy for metastatic urothelial carcinoma

  2025influential citation
• Risks of haematological malignancies in patients treated for solid tumours associated with the use of pegylated granulocyte colony-stimulating factors: A single centre study since 2005

  2025cites this paper
• Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report

  2025cites this paper
• Temporal Trends of Subsequent CNS Malignancies Among Survivors of Childhood Cancer.

  2025cites this paper
• FAN1-mediated translesion synthesis and POLQ/HELQ-mediated end joining generate interstrand crosslink-induced mutations

  2025cites this paper
• A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.

  2025cites this paper
• Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

  2025cites this paper
• Occupational Exposure Risk and Safety of Novel Intraperitoneal Oxaliplatin Delivery via Heated CO2 and Dual-Flow Nozzle System

  2025cites this paper
• Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor

  2024cites this paper
• Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights

  2024cites this paper
• Keratinocyte Carcinomas in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study.

  2024cites this paper
• Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment

  2024cites this paper
• Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial.

  2024cites this paper
• Second primary cancers in patients with a pharyngeal index tumour: a register-based cohort study

  2024cites this paper
• Late subsequent leukemia after childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)

  2024cites this paper
• Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt

  2024cites this paper
• Bladder Adenocarcinoma in a Constellation of Multiple Site Malignancies: An Unusual Case and Systematic Review

  2024cites this paper
• Synchronous Primary Gallbladder and Colon Adenocarcinoma: A Case Report and Systematic Literature Review

  2024cites this paper
• Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis

  2024cites this paper
• Subsequent malignant neoplasms after primary hematological malignancy in adult patients

  2024cites this paper
• Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer.

  2024cites this paper
• Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.

  2024cites this paper
• Advances in the care of breast cancer survivors

  2023cites this paper
• Prediabetes and Associated Risk of Cardiovascular Events and Chronic Kidney Disease Among Adult Survivors of Childhood Cancer in the St Jude Lifetime Cohort

  2023cites this paper
• Impact of fractionated cisplatin and radiation treatment on cell growth and accumulation of DNA damage in two normal cell types differing in origin

  2023cites this paper
• Research Progress of Multiple Primary Malignancies Associated With Esophageal Cancer

  2023cites this paper
• Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy

  2023cites this paper
• Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.

  2023cites this paper
• Hirsutidin Prevents Cisplatin-Evoked Renal Toxicity by Reducing Oxidative Stress/Inflammation and Restoring the Endogenous Enzymatic and Non-Enzymatic Level

  2023cites this paper
• Susceptibility Genes Associated with Multiple Primary Cancers

  2023cites this paper
• Epigenetically programmed resistance to chemo- and immuno-therapies.

  2023cites this paper
• Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention

  2023cites this paper
• Therapy-related acute myeloid leukemia with CBFB/MYH11 in a patient with ovarian cancer after exposure to chemotherapy

  2023cites this paper
• Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

  2023cites this paper
• Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.

  2023cites this paper
• Prevalence of pathogenic variants in cancer‐predisposing genes in second cancer after childhood solid cancers

  2023cites this paper
• A Case of Squamous Cell Carcinoma of Mandibular Gingiva With Treatment-related Myelodysplastic Syndrome After Paclitaxel, Carboplatin and Cetuximab Therapy

  2023cites this paper
• Neuroblastoma survivors at risk for developing subsequent neoplasms: A systematic review.

  2022cites this paper
• Second primary malignancies after ovarian cancer: A SEER-based analysis (1975-2016).

  2022cites this paper
• Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects

  2022cites this paper
• Polyneuropathy in Adolescent Childhood Cancer Survivors: The PACCS Study.

  2022cites this paper
• Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.

  2022cites this paper
• Synchronous/Metachronous Multiple Primary Malignancies: Review of Associated Risk Factors

  2022influential citation
• Acute Leukemias

  2021cites this paper
• Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS).

  2021cites this paper
• A Case of Recurrent Ovarian Cancer and Therapy-Related Acute Myeloid Leukemia Treated with Azacitidine

  2021cites this paper
• Colorectal Cancer Risk in Women with Gynecologic Cancers—A Population Retrospective Cohort Study

  2021cites this paper
• Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.

  2021cites this paper
• A narrative review of radiation-related malignancy in the pelvis

  2021cites this paper
• 1. Title: Updated Epidemiology of Secondary CNS Malignancy Following Radiotherapy Exposure in Childhood Cancer Survivors 2. Working group and investigators: This project will be developed through the SMN Working Group. Proposed investigators include:

  2021cites this paper
• Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.

  2021cites this paper
• Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

  2021cites this paper
• Subsequent Malignant Neoplasms in Retinoblastoma Survivors

  2021cites this paper
• Treatment‐related leukemia after taxane and platinum therapy in gynecological cancer patients (Gynecologic Oncology Trial and Investigation Consortium 011)

  2021cites this paper
• Lung Cancer as a Subsequent Malignant Neoplasm in Survivors of Childhood Cancer

  2021cites this paper
• Current Ovarian Cancer Maintenance Strategies and Promising New Developments

  2021cites this paper
• A case of carcinoma of the buccal mucosa with the development of therapy-related myelodysplastic syndrome

  2021cites this paper
• From the DEPARTMENT OF MOLECULAR MEDICINE AND SURGERY Karolinska Institutet, Stockholm, Sweden EWING SARCOMA; TREATMENT, PROGNOSIS AND LATE EFFECTS

  2020cites this paper
• Cisplatin's dual-effect on the circadian clock triggers proliferation and apoptosis

  2020cites this paper
• Fanconi anemia-independent DNA inter-strand crosslink repair in eukaryotes.

  2020cites this paper
• Insights into the Pathobiology of Secondary AML

  2020cites this paper
• Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients.

  2020cites this paper
• The Risk of Secondary Malignancies in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis

  2020cites this paper
• Mitochondrial relocation of a common synthetic antibiotic: A non-genotoxic approach to cancer therapy.

  2020cites this paper
• Incidence of radiation induced sarcoma attributable to radiotherapy in adults: A retrospective cohort study in the SEER cancer registries across 17 primary tumor sites

  2020cites this paper
• Leucemia mieloide aguda secundaria al tratamiento de los tumores ginecológicos: a propósito de dos casos

  2020cites this paper
• Risk of second primary cancer in oral squamous cell carcinoma

  2020cites this paper
• Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.

  2020cites this paper
• The clinicopathologic features of multiple primary malignancies in hematology: A cross sectional descriptive study

  2020influential citation
• Testicular Cancer as a Model for Understanding the Impact of Evolving Treatment Strategies on the Long-Term Health of Cancer Survivors.

  2020cites this paper
• Continuing increased risk of second cancer in long‐term testicular cancer survivors after treatment in the cisplatin era

  2020cites this paper
• Therapy-related acute myeloid leukemia and its prevention.

  2020cites this paper
• Subsequent malignant neoplasms among children with Hodgkin lymphoma: A report from the Children's Oncology Group.

  2020cites this paper
• Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

  2019cites this paper
• Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent

  2019cites this paper
• Myeloid malignancies after treatment for solid tumours.

  2019cites this paper
• CMAR_A_200524 4371..4390

  2019cites this paper
• Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era

  2019cites this paper
• Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

  2019cites this paper
• Photo-induced DNA interstrand cross-links formed by a coumarin-modified nucleoside

  2019cites this paper
• Pharmaceutical Management of Ovarian Cancer: Current Status

  2019cites this paper
• Therapy Related Acute Lymphoblastic Leukemia (t-ALL): Case Report and Literature Review

  2019cites this paper
• Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort.

  2019cites this paper
• Oncologic therapy shapes the fitness landscape of clonal hematopoiesis

  2019cites this paper
• Germline polymorphisms and the risk of therapy-related myeloid neoplasms.

  2019cites this paper
• Late‐onset anorectal disease and psychosocial impact in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study

  2019cites this paper
• Common B-cell acute lymphoblastic leukaemia in a 70-year-old woman presenting 2 years after carboplatin-taxane radiotherapy for endometrial cancer

  2019influential citation
• Cisplatyna : dokumentacja proponowanych dopuszczalnych wielkości narażenia zawodowego

  2018cites this paper
• Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

  2018cites this paper
• Stratégie thérapeutique des neuropathies périphériques chimio-induites

  2018cites this paper
• Acute Myeloid Leukemia Following Gynecologic Cancer in the Era of Platinum-Based Chemotherapy

  2018cites this paper
• Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities

  2018cites this paper
• The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.

  2018cites this paper
• Therapy‐related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients

  2018cites this paper
• Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.

  2018cites this paper
• Metal Drugs and the Anticancer Immune Response.

  2018cites this paper